Progestational potency of oral contraceptives

Area of Science:

• Endocrinology
• Pharmacology
• Reproductive Biology

Background:

• Progestins are crucial in hormonal therapies and contraception.
• Accurate assessment of progestational potency is vital for drug development and clinical application.
• Existing methods for potency estimation have limitations.

Purpose of the Study:

• To compare the efficacy of glycogen deposition assay versus the delay of menses assay for estimating progestational potency.
• To determine the relative potency of various progestins, including norgestrel.
• To evaluate the progestational potency of different oral contraceptive formulations.

Main Methods:

• Utilized the induction of glycogen deposition as subnuclear vacuoles to assess progestational activity.
• Employed the delay of menses assay as a comparative method.
• Calculated oral contraceptive potency by multiplying individual progestin potency by their respective doses.

Main Results:

• Glycogen deposition assay proved superior to the delay of menses assay for estimating progestational potency.
• Norgestrel exhibited the highest progestational potency across all tested assays.
• Oral contraceptives containing norgestrel were found to be in the mid-range of progestational potency due to norgestrel's high potency.
• No significant difference in progestational potency was observed between norethindrone 'mini' pill, norethindrone low-progestogen combination pill, and sequential pill over a 28-day cycle.

Conclusions:

• The glycogen deposition assay is a more reliable method for quantifying progestational potency.
• Norgestrel's high potency significantly influences the overall progestational strength of oral contraceptives.
• Different formulations of norethindrone-containing oral contraceptives may offer comparable progestational effects at the studied doses.